| Project/Area Number |
23618003
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Regenerative medicine
|
|---|
| Research Institution | Tohoku University |
|---|
Principal Investigator |
SATO Takeya 東北大学, 医学(系)研究科(研究院), 助教 (10312696)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
YANAGISAWA Teruyuki 東北大学, 大学院医学系研究科, 教授 (90133941)
|
|---|
| Co-Investigator(Renkei-kenkyūsha) |
SUKEGAWA Jun 東北大学, 大学院医学系研究科, 准教授 (30187687)
|
|---|
| Project Period (FY) |
2011 – 2013
|
| Project Status |
Completed (Fiscal Year 2013)
|
| Budget Amount *help |
¥5,460,000 (Direct Cost: ¥4,200,000、Indirect Cost: ¥1,260,000)
Fiscal Year 2013: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2012: ¥2,080,000 (Direct Cost: ¥1,600,000、Indirect Cost: ¥480,000)
Fiscal Year 2011: ¥2,080,000 (Direct Cost: ¥1,600,000、Indirect Cost: ¥480,000)
|
|---|
| Keywords | 細胞 / トランスレーショナルリサーチ / 再生医学 / 薬剤反応性 / 細胞・組織 / 発生・分化 |
|---|
| Research Abstract |
Induced pluripotent stem cells are known to possess ability to differentiate into various types of cells and to proliferate infinitely in vitro. Whereas, these characters of iPS cells often induce tumor formation and irritable immune reactions against the host cells following differentiate into immunocompetent cells. Thus, involvement of "suicide genes" is prerequisite to reserve safety of iPS cells in the application of regenerative medicine. Our novel suicide gene approach utilizes a gene for human thymidylate kinase (tmpk) in combination with a non-toxic prodrug, azido-thymidine (AZT) which is converted into toxic metabolites, AZT-triphosphate that leads to induce cell death. We chose the CR4 promoter for tmpk gene that expresses only undifferentiated iPS cells to ensure the safety of usage of differentiated iPS cells by removing residual undifferentiated cells in the differentiated cell cluster after AZT-administration. We have validated effectiveness of our approach in vitro.
|
